A growing number of clinically unique immunomodulatory disease-modifying therapies (DMTs) are approved for the treatment of relapsing forms of multiple sclerosis (MS), the most prevalent form of MS. Nevertheless, all approved drugs have clinical shortcomings in terms of efficacy, safety, tolerability, and/or delivery, creating opportunities for new and improved DMTs, be they next-in-class or pioneering. This content provides quantitative insight into U.S. and European physicians’ perceptions of key treatment drivers and goals in the management of relapsing forms of MS and the current level of unmet need in this area. We analyze the commercial opportunities and how new / emerging novel and next-generation compounds may capitalize on these opportunities.
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 U.S. and 31 European neurologists fielded in April 2021
Key companies: Novartis, Bristol Myers Squibb, Biogen, Merck KGaA, Teva, Roche / Genentech, Janssen, TG Therapeutics, Mapi Pharma, Sanofi Genzyme
Key drugs: Gilenya, Mayzent, Zeposia, Tecfidera / dimethyl fumarate, Vumerity, Mavenclad, Copaxone / glatiramer acetate, Tysabri, Ocrevus, Kesimpta